Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactic acid bacterial microbiome formulation
- Development stage
- Unknown
- Lead developer
- Lund University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
A topical live biotherapeutic product (LBP) consisting of a consortium of nine specific lactic acid bacterial (LAB) strains originally isolated from the honey stomach of honeybees. Developed by researchers at Lund University, this formulation is designed for the treatment of chronic venous leg ulcers. The consortium includes multiple strains of *Lactobacillus plantarum*, along with *Lactobacillus paracasei*, *Lactobacillus brevis*, *Lactobacillus coryniformis*, *Lactobacillus salivarius*, and *Lactobacillus kunkeei*. These bacteria work synergistically to produce a range of antimicrobial metabolites, including lactic acid, hydrogen peroxide, and bacteriocins, which inhibit the growth of multi-drug resistant wound pathogens such as MRSA and *Pseudomonas aeruginosa*. Beyond its antimicrobial properties, the formulation is intended to promote wound healing by modulating the local inflammatory environment and stimulating tissue regeneration.
- Other names
- LAB formulationHoneybee lactic acid bacteria formulationLactic acid bacteria formulation
02
Targets
Wound microbiome community structure
Beyond the preview
Go deeper on lactic acid bacterial microbiome formulation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactic acid bacterial microbiome formulation.